Cargando…

PB1763: A PHASE 1/2 STUDY TO EVALUATE PONATINIB WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RELAPSED/RESISTANT/INTOLERANT PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR WITH T315I MUTATION

Detalles Bibliográficos
Autores principales:	Gore, L., Loh, M., Pui, C.-H., Matloub, Y., Hanley, M. J., Du, J., Hennessy, M., Granier, M., Biondi, A., Silverman, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431202/ http://dx.doi.org/10.1097/01.HS9.0000849908.11106.d2

Ejemplares similares

PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
por: Jabbour, E., et al.
Publicado: (2022)

PB1740: THE COMBINATION OF PONATINIB PLUS CHEMOTHERAPY UPFRONT ACHIEVES DURABLE COMPLETE MOLECULAR REMISSIONS IN ADULTS PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Sotirios, Papageorgiou, et al.
Publicado: (2023)

Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia
por: Wang, Huafeng, et al.
Publicado: (2022)

PB1757: VARIANT PHILADELPHIA CHROMOSOME IN ALL
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation
por: Nicolini, Franck E., et al.
Publicado: (2017)

PB1711: DROPLET DIGITAL PCR DETECTION OF THE T315I BCR::ABL1 KD MUTATION IN ADULT PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Cardinali, Deborah, et al.
Publicado: (2023)

PB1891: VARIANT PHILADELPHIA CHROMOSOME IN CML
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

Monitoring Ponatinib in a Child with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Tanimura, Kazuki, et al.
Publicado: (2021)

Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2022)

Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
por: Giudice, Valentina, et al.
Publicado: (2020)

PB1763: THE CELLULAR UPTAKE OF CPX-351 BY SCAVENGER RECEPTOR CLASS B TYPE 1-MEDIATED NONENDOCYTIC PATHWAY IN LEUKEMIA CELLS.
por: Araie, Hiroaki, et al.
Publicado: (2023)

PB1742: FEASIBILITY AND EFFICACY OF A PEG-ASPARAGINASE-BASED TREATMENT PROTOCOL IN ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
por: Vernarecci, Chiara, et al.
Publicado: (2023)

PB1843: ACUTE MYELOID LEUKEMIA WITH PHILADELPHIA CHROMOSOME: EXPERIENCE OF SFAX HEMATOLOGY DEPARTMENT
por: Siala, N., et al.
Publicado: (2022)

PB2054: HIP AND KNEE OSTEOARTHRITIS IN PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Holik, H., et al.
Publicado: (2022)

PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES
por: Shadman, M., et al.
Publicado: (2022)

Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2021)

PB1754: TELOMERE LENGTH IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
por: Vakonaki, E., et al.
Publicado: (2022)

PB2212: ABDOMINAL AORTIC CALCIFICATION IN PATIENTS NEWLY DIAGNOSED WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASM
por: Lee, Myung-Won, et al.
Publicado: (2023)

PB1748: DIFFERENTIAL IRON HOMEOSTASIS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN VITRO MODELS
por: Capelletti, M. M., et al.
Publicado: (2022)

PB2058: IMPACT OF COMORBIDITIES AND RESPONSE TO TREATMENT ON THE MPN SAF ASSESSMENT OF PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE SYNDROMES.
por: Mohamed, B., et al.
Publicado: (2022)

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
por: Anagnostou, Theodora, et al.
Publicado: (2017)

PB2048: HEMATOLOGIC RECOVERY INDUCED BY AVATROMBOPAG IN SAA REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG
por: Liu, Xiaoqing, et al.
Publicado: (2023)

PB1726: HEARING STATUS OF SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
por: Mahfouz, Asmaa, et al.
Publicado: (2023)

PB1739: ADVERSE EFFECTS OF ASPARAGINASE IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
por: Chenbah, Wafa, et al.
Publicado: (2023)

PB1750: PHILADELPHIA CHROMOSOME POSITIVE ALL EGYPTIAN PATIENTS: CLINICAL PROFILE & OUTCOME. A SINGLE CENTER EXPERIENCE.
por: Shaaban, Yasmine, et al.
Publicado: (2023)

PB1724: NILOTINIB PLUS CHEMOTHERAPY IN PEDIATRICS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LEUKEMIA: A SINGLE CENTER EXPERIENCE
por: LI, Yanming, et al.
Publicado: (2023)

PB1754: HOMOZYGOUS DELETION OF ETV6: EARLY T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA OR PRECURSOR T-LYMPHOBLASTIC LYMPHOMA
por: Álvarez, Miguel Ángel Perera, et al.
Publicado: (2023)

PB1766: PROGNOSTIC SIGNIFICANCE OF ACTIVIN A IN ADULT EGYPTIAN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Azzazi, M., et al.
Publicado: (2022)

PB1755: CASPASE 8, CASPASE 10 AND FAS GENE POLYMORPHISMS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
por: Lourou, M., et al.
Publicado: (2022)

PB1702: ACTIVINA MODULATES THE MICRORNA CARGO OF EXTRACELLULAR VESICLES RELEASED BY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL) CELLS
por: Licari, Eugenia, et al.
Publicado: (2023)

P364: A PHASE II STUDY OF LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AND PONATINIB FOLLOWED BY BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Haddad, Fadi, et al.
Publicado: (2023)

PB1767: OUTCOME OF RELAPSED CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN THE SOUTH OF TUNISIA SINGLE CENTER EXPERIENCE
por: Siala, N., et al.
Publicado: (2022)

PB1745: SURVIVAL AND PROGNOSTIC FACTORS OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN OMAN.
por: Almamari, Moza, et al.
Publicado: (2023)

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]
Publicado: (2018)

Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison
por: Ribera, Josep-Maria, et al.
Publicado: (2023)

PB1764: THE CHARACTERISTICS, TREATMENT PATTERNS, AND SURVIVAL OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) TREATED BY GRAALL OR GRAAPH PROTOCOL
por: Fakhfakh, Y., et al.
Publicado: (2022)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

PB1717: CD19-NEGATIVE B- ACUTE LYMPHOBLASTIC LEUKEMIA: WHAT CHALLENGES?
por: Siala, Nour, et al.
Publicado: (2023)

PB1722: EARLY T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSIS AND TREATMENT CHALLENGES
por: Siala, Nour, et al.
Publicado: (2023)

PB1746: EVOLUTION OF SARS-COV-2 INFECTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
por: Guerbouj, Hamida Khémiri, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9bat66vk39hhqjsvfg0dpesi1v